🇺🇸 FDA
Patent

US 6506799

Methods of treating cardiovascular diseases, dyslipidemia, dyslipoproteinemia, and hypertension with ether compounds

expired A61PA61P1/18A61P13/12

Quick answer

US patent 6506799 (Methods of treating cardiovascular diseases, dyslipidemia, dyslipoproteinemia, and hypertension with ether compounds) held by Esperion Therapeutics, Inc. expires Mon Jan 09 2023 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
Esperion Therapeutics, Inc.
Grant date
Tue Jan 14 2003 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 09 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
27
CPC classes
A61P, A61P1/18, A61P13/12, A61P15/10, A61P25/28